Pfizer Inc. is asking the FDA to become the speech police to protect the U.S.'s emerging biosimilar market from innovators' verbal assaults. Pfizer petitioned the agency to issue guidance spelling out what's inappropriate or would be considered misleading for the sponsors of reference biologics to say about biosimilars and interchangeables.